中外創薬 助成研究報告書2023
233/324

15. Suzuki N, Iwamura Y, Nakai T, Kato K, Otsuki A, Uruno A, Saigusa D, Taguchi K, Suzuki M, Shimizu R, Yumoto A, Okada R, Shirakawa M, Shiba D, Takahashi S, Suzuki T, Yamamoto M: Gene expression changes related to bone mineralization, blood pressure and lipid metabolism in mouse kidneys after space travel. Kidney International, 101 (1), 92–105 (2022). doi: 10.1016/j.kint.2021.09.031. 18. Nakai T, Iwamura Y, Suzuki N: Efficient isolation of interstitial fibroblasts directly from mouse kidneys or ― 231 ― 14. Nezu M, Souma T, Yu L, Suzuki T, Saigusa D, Ito S, Suzuki N, Yamamoto M: Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression. Kidney International, 91 (2), 387–401 (2017). doi: 10.1016/j.kint.2016.08.023.16. Suzuki N, Matsuo-Tezuka Y, Sasaki Y, Sato K, Miyauchi K, Kato K, Saito S, Shimonaka Y, Hirata M, Yamamoto M: Iron attenuates erythropoietin production by decreasing HIF2a concentrations in renal interstitial fibroblasts. Kidney International, 94 (5), 900–911 (2018). doi: 10.1016/j.kint.2018.06.028.17. Suzuki N, Sasaki Y, Kato K, Yamazaki S, Kurasawa M, Yorozu K, Shimonaka Y, Yamamoto M: Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice. Haematologica, 101 (9), e356–360 (2016). doi: 10.3324/haematol.2015.140814.indirectly after ex vivo expansion. STAR Protocols, 2, 100826, 2021. doi: 10.1016/j.xpro.2021.100826.

元のページ  ../index.html#233

このブックを見る